// startup autopsy
APT Pharmaceuticals
Drug developer that ran out of runway before reaching the clinic
marketfitSilent Shutdown
Quiet closure with no public announcement · Fatal mistake: APT Pharmaceuticals failed to secure follow-on financing commitments before the 2008 financial crisis froze biotech investment, leaving its drug pipeline without sufficient capital to reach regulatory milestones.
Key Events Timeline
FOUNDING
APT Pharmaceuticals founded to develop novel drug compounds targeting unmet medical needs.
FUNDING
APT raises significant capital during the mid-2000s biotech funding wave to advance clinical pipeline.
FUNDING
APT closes its final $54M total funding round just as global financial markets begin to seize up.
REGULATORY ACTION
Clinical trial setbacks or FDA feedback delays APT's path to approval, stretching cash reserves dangerously thin.
SHUTDOWN
APT Pharmaceuticals shuts down after exhausting its $54M without achieving regulatory approval or a licensing deal.